List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. USING AL TO ENHANCE VR ANXIETY DISORDER TREATMENT

    SBC: ARGUS VR INTERNATIONAL            Topic: N/A

    DESCRIPTION (provided by applicant) This project will develop an artificial intelligence to provide the core functionality for virtual reality and computer based treatments for anxiety disorders. The use of artificial intelligence offers a number of advantages over existing treatments: (1) artificial intelligence provides personalized treatment - using multiple real time physiologic and subjective ...

    STTR Phase I 2002 Department of Health and Human Services
  2. DEVELOPMENT OF A BIOLOGICALLY-ACTIVE VASCULAR GRAFT

    SBC: BIOMOD SURFACES            Topic: N/A

    Medium (6-8mm) and small (

    STTR Phase I 2002 Department of Health and Human Services
  3. DEVELOPMENT OF A BIOLOGICALLY-ACTIVE VASCULAR GRAFT

    SBC: BIOMOD SURFACES            Topic: N/A

    Medium (6-8mm) and small (

    STTR Phase II 2002 Department of Health and Human Services
  4. NANOFIBER TECHNOLOGY IN SMALL-DIAMETER VASCULAR GRAFTS

    SBC: BIOMOD SURFACES            Topic: N/A

    There is no small-diameter vascular prosthesis that is capable of emulating the biologic and physical properties of the normal arterial wall. The goal of this proposal is to develop a small-diameter prosthetic vascular graft using nanofiber technology. Our hypothesis is creating a nanofibrous vascular graft by electrospinning an ionic polyurethane will result in a graft that possesses properties s ...

    STTR Phase I 2002 Department of Health and Human Services
  5. DEVELOPMENT OF A MIDDLE EAR BALLOON IMPLANT

    SBC: BOSTON MEDICAL PRODUCTS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Development of a new type of middle ear implant, a "middle ear balloon" is proposed. This implant is intended to restore hearing in non-aerated ears by creating and permanently maintaining an air or gas-filled space within the middle ear. Non-aerated middle ears resulting from eustachian tube dysfunction camonly occur in chronic otitis media (COM) and in otitis ...

    STTR Phase I 2002 Department of Health and Human Services
  6. DEVELOPMENT OF A MIDDLE EAR BALLOON IMPLANT

    SBC: BOSTON MEDICAL PRODUCTS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Development of a new type of middle ear implant, a "middle ear balloon" is proposed. This implant is intended to restore hearing in non-aerated ears by creating and permanently maintaining an air or gas-filled space within the middle ear. Non-aerated middle ears resulting from eustachian tube dysfunction camonly occur in chronic otitis media (COM) and in otitis ...

    STTR Phase II 2002 Department of Health and Human Services
  7. IDENTIFICATION AND EXPRESSION OF INSECTICIDE TARGETS

    SBC: CAMBRIA BIOSCIENCES, LLC            Topic: N/A

    DESCRIPTION (Provided by applicant): Insect-borne infectious diseases such as malaria affect at least 1 billion people worldwide, and over 1.5 million of these infected individuals die each year. Malarial parasites and many other vector-borne pathogens have developed resistance to current drugs, and vaccines are not available or feasible for many of these pathogens. Insect vector control programs ...

    STTR Phase I 2002 Department of Health and Human Services
  8. ORAL THERAPEUTIC FOR INDUCING FETAL HEMOGLOBIN

    SBC: Gene Regulation Laboratories            Topic: N/A

    DESCRIPTION (provided by applicant): Sickle cell disease (SCD) and beta-thalassemia are genetic disorders caused by molecular mutations affecting the genes for adult hemoglobin. With a world-wide birth prevalence of 2/1,000, hemoglobin disorders are the most common genetic diseases in the world (360,000 patients/year - 250,000 with sickling disorders and 110,000 with thalassemias. These conditions ...

    STTR Phase I 2002 Department of Health and Human Services
  9. ORAL THERAPEUTIC FOR INDUCING FETAL HEMOGLOBIN

    SBC: Gene Regulation Laboratories            Topic: N/A

    DESCRIPTION (provided by applicant): Sickle cell disease (SCD) and beta-thalassemia are genetic disorders caused by molecular mutations affecting the genes for adult hemoglobin. With a world-wide birth prevalence of 2/1,000, hemoglobin disorders are the most common genetic diseases in the world (360,000 patients/year - 250,000 with sickling disorders and 110,000 with thalassemias. These conditions ...

    STTR Phase II 2002 Department of Health and Human Services
  10. ORAL THERAPEUTICS FOR VIRAL MALIGNANCIES

    SBC: Gene Regulation Laboratories            Topic: N/A

    DESCRIPTION (provided by applicant): Epstein-Barr virus (EBV) is associated with a number of human lymphoid malignancies and carcinomas for which there are presently few effective treatments. Each year in the U.S., there are approximately 27,000 people afflicted with diseases caused by the Epstein-Barr virus, and an additional 107,000 people afflicted with malignancies associated with the Epstein ...

    STTR Phase I 2002 Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government